Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis

Epidemiology and Infection

Volumn 129, Issue 3, 2002, Pages 479-489

  Teunis, P F M ^a   van der Heijden, O G ^a   de Melker, H E ^a   Schellekens, J F P ^a   Versteegh, F G A ^b   Kretzschmar, M E E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b GROENE HART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PERTUSSIS TOXIN;

ADOLESCENT; ADULT; ANALYTICAL ERROR; ANTIBODY RESPONSE; ANTIBODY TITER; BORDETELLA PERTUSSIS; CALCULATION; CHILD; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFANT; INFECTION RATE; KINETICS; MAJOR CLINICAL STUDY; MEDICAL RECORD; NONLINEAR REGRESSION ANALYSIS; PERTUSSIS; REVIEW; SEROLOGY; STATISTICAL MODEL;

EID: 0036978359     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0950268802007896     Document Type: Review

References (25)

1. de Melker HE, Versteegh FGA, Conyn van Spaendonck MAE, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000; 38: 800-6.
2. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28: 1230-7.
3. Tomoda T, Ogura H, Kurashige T. Immune responses to Bordetella pertussis infection and vaccination. J Infect Dis 1991; 163: 559-63.
4. Tomoda T, Ogura H, Kurashige T. The longevity of the immune response to filamentous hemagglutinin and pertussis toxin in patients with pertussis in a semiclosed community. J Infect Dis 1992; 166: 908-10.
5. Isacson J, Trollfors B, Hedvall G, Taranger J, Zackrisson G. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Scand J Infect Dis 1995; 27: 273-7.
6. Giammanco A, Taormina S, Genovese M, Mangiaracina G, Giammanco G, Chiarini A. Serological responses to infection with B. pertussis. Dev Biol Standard 1997; 89: 213-20.
7. Di Tommaso A, Bartalini M, Peppoloni S, Podda A, Rappuoli R, De Magistris MT. Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. Vaccine 1997; 15: 1218-24.
8. Giuliano M, Mastrantonio P, Giammanco A, et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Dev Biol Standard 1997; 89: 275-8.
9. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SGF. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998; 132: 983-8.
10. Bell F, Martin A, Blondeau C, Thronton C, Chaplais J, Finn A. Combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccines for primary immunisation. Arch Dis Child 1996; 75: 298-303.
11. de Melker HE, Schellekens JFP, Neppelenbroek SE, Mooi FR, Rümke HC, Conyn van Spaendonck MAE. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 2000; 6: 348-57.
12. Versteegh FGA, Schellekens JFP, Nagelkerke AF, Roord JJ. Laboratory-confirmed reinfections with Bordetella pertussis. Acta Paediatr 2002; 91: 95-7.
13. Nagel J, de Graaf S, Schijf Evers D. Improved sero-diagnosis of whooping cough caused by Bordetella pertussis by determination of IgG anti-LPF antibody levels. Dev Biol Standard 1985; 61: 325-30.
14. de Melker HE. Seroepidemiology of diphtheria, tetanus, poliomyelitis and pertussis. PhD thesis, Wageningen University, 1999.
15. Gilks WR, Richardson S, Spiegelhalter DJ, editors. Markov Chain Monte Carlo in practice. London: Chapman and Hall, 1996.
16. Teunis PFM, Evers EC, Slob W. Analysis of variable fractions resulting from microbial counts. Quant Microbiol 1999; 1: 63-88.
17. van Herck K, Beutels P, van Damme P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000; 60: 1-7.
18. Huang LM, Lee CY, Lin TY, Chen JM, Lee PI, Hsu CY. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age. Vaccine 1996; 14: 916-22.
19. Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response [see comments]. J Infect Dis 1990; 161: 487-92. J Infect Dis 1990; 161: 473-9.
20. Hall E, Parton R, Wardlaw AC. Time-course of infection and responses in a coughing rat model of pertussis. J Med Microbiol 1999; 48: 95-8.
21. Gay NJ. Analysis of serological surveys using mixture models: application to a survey of parvovirus B19. Stat Med 1996; 15: 1567-73.
22. Auranen K, Eichner M, Kayhty H, Takala AK, Arjas E. A hierarchical Bayesian model to predict the duration of immunity to Haemophilus influenzae type b. Biometrics 1999; 55: 1306-13.
23. Auranen K. Back-calculating the age-specific incidence of recurrent subclinical Haemophilus influenzae type b infection. Stat Med 2000; 19: 281-96.
24. van Herck K, van Damme P. Inactivated hepatitis a vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63: 1-7.
25. Tiru M, Hallander HO, Gustafsson L, Storsaeter J, Olin P. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine 2000; 181: 2295-306.